NIS 102m. approved for R&D projects

Among the winners were six telecommunications projects securing NIS 72.3m., four chemical projects awarded NIS 5m., and three projects in electronics and electro-optics which received NIS 24.3m.

By ZEV STUB
March 29, 2006 07:01

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The Industry, Trade, and Labor Ministry said Monday it recently approved investments totaling NIS 102 million for 13 research and development projects. Of that sum, NIS 43m. came from government grants. Among the winners were six telecommunications projects securing NIS 72.3m., four chemical projects awarded NIS 5m., and three projects in electronics and electro-optics which received NIS 24.3m. The ministry also said it approved seven companies for tax benefits to help them reinvest in future R&D, as described in the Investment Encouragement law.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS